Targeting PTB as a One-Step Procedure for In Situ Astrocyte-to-Dopamine Neuron Reprogramming in Parkinson's Disease.
作者信息
Jiang Yuanyuan, Wang Yongjie, Huang Zhihui
机构信息
Department of Neurosurgery of The Affiliated Hospital, Holistic Integrative Pharmacy Institutes, Hangzhou Normal University, Hangzhou, 311121, China.
Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China.
出版信息
Neurosci Bull. 2021 Mar;37(3):430-432. doi: 10.1007/s12264-021-00630-x. Epub 2021 Jan 13.
Abstract
摘要
相似文献
1
Targeting PTB as a One-Step Procedure for In Situ Astrocyte-to-Dopamine Neuron Reprogramming in Parkinson's Disease.将PTB作为帕金森病原位星形胶质细胞向多巴胺能神经元重编程的一步法靶点。
Neurosci Bull. 2021 Mar;37(3):430-432. doi: 10.1007/s12264-021-00630-x. Epub 2021 Jan 13.
2
Treating Parkinson's disease by astrocyte reprogramming: Progress and challenges.通过星形胶质细胞重编程治疗帕金森病：进展与挑战。
Sci Adv. 2021 Jun 23;7(26). doi: 10.1126/sciadv.abg3198. Print 2021 Jun.
3
Astrocyte-to-neuron reprogramming and crosstalk in the treatment of Parkinson's disease.星形胶质细胞到神经元的重编程及其在帕金森病治疗中的相互作用。
Neurobiol Dis. 2023 Aug;184:106224. doi: 10.1016/j.nbd.2023.106224. Epub 2023 Jul 9.
4
TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.星形胶质细胞上的TRPV1通过睫状神经营养因子拯救帕金森病中的黑质多巴胺能神经元。
Brain. 2015 Dec;138(Pt 12):3610-22. doi: 10.1093/brain/awv297. Epub 2015 Oct 21.
5
Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.Cav1.3 通道通过 NCS-1 控制黑质多巴胺神经元中的 D2 自身受体反应。
Brain. 2014 Aug;137(Pt 8):2287-302. doi: 10.1093/brain/awu131. Epub 2014 Jun 16.
6
Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA.星形胶质细胞功能障碍持续时间延长和小胶质细胞激活加速了大鼠黑质多巴胺能神经元的变性，并阻断了 6-OHDA 诱导的早期运动功能障碍的代偿。
Mol Neurobiol. 2018 Apr;55(4):3049-3066. doi: 10.1007/s12035-017-0529-z. Epub 2017 May 2.
7
Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.排斥导向分子a（RGMa）诱导出与帕金森病极为相似的神经病理和行为变化。
J Neurosci. 2017 Sep 27;37(39):9361-9379. doi: 10.1523/JNEUROSCI.0084-17.2017. Epub 2017 Aug 21.
8
Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.人类帕金森病多巴胺缺乏症中的脑单胺氧化酶B和A
Brain. 2017 Sep 1;140(9):2460-2474. doi: 10.1093/brain/awx172.
9
Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection.米氮平发挥星形胶质细胞介导的多巴胺能神经保护作用。
Sci Rep. 2020 Nov 26;10(1):20698. doi: 10.1038/s41598-020-77652-4.
10
Generation of a Novel Mouse Model of Parkinson's Disease via Targeted Knockdown of Glutamate Transporter GLT-1 in the Substantia Nigra.通过在黑质中靶向敲低谷氨酸转运体 GLT-1 生成新型帕金森病小鼠模型。
ACS Chem Neurosci. 2020 Feb 5;11(3):406-417. doi: 10.1021/acschemneuro.9b00609. Epub 2020 Jan 21.
引用本文的文献
1
Base editing of in neurons alleviates symptoms in a mouse model of Parkinson's disease.神经元中碱基编辑可缓解帕金森病小鼠模型的症状。
Elife. 2024 Dec 23;13:RP97180. doi: 10.7554/eLife.97180.
2
Small molecules reprogram reactive astrocytes into neuronal cells in the injured adult spinal cord.小分子可将损伤成年脊髓中的反应性星形胶质细胞重编程为神经元细胞。
J Adv Res. 2024 May;59:111-127. doi: 10.1016/j.jare.2023.06.013. Epub 2023 Jun 26.
3
Mechanisms Underlying Brain Aging Under Normal and Pathological Conditions.正常和病理条件下大脑老化的潜在机制。
Neurosci Bull. 2023 Feb;39(2):303-314. doi: 10.1007/s12264-022-00969-9. Epub 2022 Nov 27.
4
Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease.在帕金森病的 6-羟多巴胺小鼠模型中，抑制 PTBP1 未能将反应性星形胶质细胞转化为多巴胺能神经元。
Elife. 2022 May 10;11:e75636. doi: 10.7554/eLife.75636.
5
Targeting PTB for Glia-to-Neuron Reprogramming In Vitro and In Vivo for Therapeutic Development in Neurological Diseases.靶向多聚嘧啶结合蛋白以在体外和体内将胶质细胞重编程为神经元用于神经疾病的治疗开发
Biomedicines. 2022 Feb 7;10(2):399. doi: 10.3390/biomedicines10020399.
6
Direct Conversion of Astrocytes to Neurons Maybe a Potential Alternative Strategy for Neurodegenerative Diseases.将星形胶质细胞直接转化为神经元可能是神经退行性疾病的一种潜在替代策略。
Front Aging Neurosci. 2021 Aug 2;13:689276. doi: 10.3389/fnagi.2021.689276. eCollection 2021.
本文引用的文献
1
Reversing a model of Parkinson's disease with in situ converted nigral neurons.利用原位转化的黑质神经元逆转帕金森病模型。
Nature. 2020 Jun;582(7813):550-556. doi: 10.1038/s41586-020-2388-4. Epub 2020 Jun 24.
2
Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice.通过 CRISPR-CasRx 实现胶质细胞向神经元的转化可缓解小鼠神经疾病症状。
Cell. 2020 Apr 30;181(3):590-603.e16. doi: 10.1016/j.cell.2020.03.024. Epub 2020 Apr 8.
3
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.反义寡核苷酸疗法治疗神经退行性疾病。
Annu Rev Neurosci. 2019 Jul 8;42:385-406. doi: 10.1146/annurev-neuro-070918-050501.
4
Dopamine in Parkinson's Disease: Precise Supplementation with Motor Planning.帕金森病中的多巴胺：结合运动规划进行精准补充。
Neurosci Bull. 2018 Oct;34(5):873-874. doi: 10.1007/s12264-018-0245-3. Epub 2018 Jun 18.
5
New approaches for brain repair-from rescue to reprogramming.新的大脑修复方法——从挽救到重编程。
Nature. 2018 May;557(7705):329-334. doi: 10.1038/s41586-018-0087-1. Epub 2018 May 16.
6
Milestones of Parkinson's Disease Research: 200 Years of History and Beyond.帕金森病研究的里程碑：200年的历史及未来
Neurosci Bull. 2017 Oct;33(5):598-602. doi: 10.1007/s12264-017-0178-2. Epub 2017 Sep 11.
7
Parkinson disease.帕金森病。
Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13.
8
Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells.小鼠、人类及干细胞中脑发育的分子多样性
Cell. 2016 Oct 6;167(2):566-580.e19. doi: 10.1016/j.cell.2016.09.027.
9
Sequential regulatory loops as key gatekeepers for neuronal reprogramming in human cells.序列调控环作为人类细胞中神经元重编程的关键守门人。
Nat Neurosci. 2016 Jun;19(6):807-15. doi: 10.1038/nn.4297. Epub 2016 Apr 25.
10
Astrocyte development: A Guide for the Perplexed.星形胶质细胞发育：困惑者指南。
Glia. 2015 Aug;63(8):1320-9. doi: 10.1002/glia.22836. Epub 2015 May 12.
Zotero 插件